Caliaro M J, Marmouget C, Guichard S, Mazars P, Valette A, Moisand A, Bugat R, Jozan S
Groupe de Pharmacologie clinique et expérimentale des médicaments anticancéreux, Centre Claudius Regaud, Toulouse, France.
Int J Cancer. 1994 Mar 1;56(5):743-8. doi: 10.1002/ijc.2910560522.
The response of 4 human ovarian carcinoma cell lines to retinoic acid was found to be related to the histological type and degree of differentiation of these tumor cells. The 2 serous cell lines NIHOVCAR3 and OVCCR1 were the most sensitive to the antiproliferative effect of RA. This inhibition was associated with morphological and biological changes that were indicative of differentiation. The undifferentiated IGROV1 cell line was not affected by RA. Since the effects of RA are thought to be mediated by nuclear retinoic acid receptors (RARs), the expression of RARs in human ovarian cancer cells was studied. RAR alpha was detected as mRNA species of 3.1 and 2.6 kb in all 4 cell lines. RAR beta was not detected in any of the cell lines, while RAR gamma (3 kb) was expressed in all of the ovarian cancer cells but at a very low level in the RA-resistant IGROV1 cells.
研究发现,4种人卵巢癌细胞系对维甲酸的反应与这些肿瘤细胞的组织学类型和分化程度有关。2种浆液性细胞系NIHOVCAR3和OVCCR1对维甲酸的抗增殖作用最为敏感。这种抑制作用与表明分化的形态学和生物学变化相关。未分化的IGROV1细胞系不受维甲酸影响。由于维甲酸的作用被认为是由核维甲酸受体(RARs)介导的,因此对人卵巢癌细胞中RARs的表达进行了研究。在所有4种细胞系中均检测到RARα的3.1 kb和2.6 kb mRNA种类。在任何细胞系中均未检测到RARβ,而RARγ(3 kb)在所有卵巢癌细胞中均有表达,但在对维甲酸耐药的IGROV1细胞中表达水平非常低。